There are alternative antibiotic preparations for treating bacterial conjunctivitis. Interestingly each new drug is tested for efficacy against chloramphenicol-an emphatic acknowledgement of its role as the gold standard for treating conjunctivitis. Few drugs have been identified as being superior, except in the treatment of Chlamydia, for which chloramphenicol is ineffective. Drugs such as Poly trim or fluoroquinalones may be as effective. Microbial keratitis is generally not treated with chloramphenicol.
Blepharitis
Blepharitis responds much less well to chloramphenicol than to other forms of treatment. There is evidence to suggest that topical fucithalmic or systemic tetracycline (particularly when blepharitis is associated with rosacea) offer effective means of dealing with this conditions. Topical antibiotics themselves do not usually have time to eliminate bacteria when given pre-operatively and chloramphenicol is no different. Most reduce the bacterial flora, which may then be further significantly reduced by application of an aqueous 5% solution of povidone iodine. Chloramphenicol is useful because of the excellent ocular penetration it provides. Subconjunctival antibiotic injection at the end of the procedure may well provide an adequate immediate antibiotic prophylaxis but there may be a continuing need for topical antibiotics in the post-operative period until the eye has healed and steroids have been reduced or withdrawn. Chloramphenicol is superior to the alternatives, particularly neomycin (especially when combined with betamethasone), but Poly trim or fluoroquinalones might be adequate alternatives. As an overall antibiotic policy, however, the lack of emergence of drug resistance in the United Kingdom and other European countries may recommend chloramphenicol.
Endophthalmitis
Leopold 6 first suggested a role for chloramphenicol in the management of endophthalmitis but vitrectomy and intravitreal antibiotic injection have probably rendered this approach obsolete. Effective levels intravitreally may be reached by systemic administration of chloramphenicol and may occasionally be appropriate when vitrectomy is not feasible. It is one of the few drugs capable of penetration into the vitreous in effective concentrations after systemic administration.
Patients with a history or family history of blood dyscrasia should not receive chloramphenicol Alternative drugs are available for almost any situation but we are not convinced that a case has been made for the total abandonment of topical chloramphenicol. Doona and Walsh l have resurrected the spectre of aplastic anaemia without new evidence implicating chloramphenicol. Guilt may be easy to demonstrate, innocence less so. For this reason in Scottish law we have a verdict of 'not proven'. The case against topical chloramphenicol appears to be not proven.
